Updated Jul 16, 2026
Masoud Maher is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market purchases: $103K.
Maher Masoud is the President and CEO of MaxCyte, Inc., a company specializing in cell engineering technologies. He has been involved in advancing the company's proprietary Flow Electroporation platform, which is essential for cell-based research and therapeutics.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | MXCT | MAXCYTE, INC. | A — Grant or award | 300.0K | $0.00 | |
| 2025-08-13 | MXCT | MAXCYTE, INC. | P — Open-market purchase | 75.0K | $1.37 | $103K |
Maher Masoud is the President and CEO of MaxCyte, Inc., a company specializing in cell engineering technologies. He has been involved in advancing the company's proprietary Flow Electroporation platform, which is essential for cell-based research and therapeutics.…
Recorded transactions: 1 open-market purchases ($103K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Masoud Maher profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.